Research Analysts Issue Forecasts for CATX Q1 Earnings

Perspective Therapeutics, Inc. (NYSE:CATX) – Lifesci Capital issued their Q1 2025 earnings per share estimates for Perspective Therapeutics in a research report issued to clients and investors on Thursday, March 27th. Lifesci Capital analyst D. Kennedy anticipates that the company will post earnings of ($0.28) per share for the quarter. Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share. Lifesci Capital also issued estimates for Perspective Therapeutics’ Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.31) EPS and FY2025 earnings at ($1.10) EPS.

A number of other research firms also recently issued reports on CATX. Wedbush restated an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a report on Wednesday, March 26th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Perspective Therapeutics in a research note on Wednesday, March 19th. Cantor Fitzgerald upgraded Perspective Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 4th. Scotiabank initiated coverage on Perspective Therapeutics in a report on Friday, March 7th. They set a “sector outperform” rating and a $15.00 price objective for the company. Finally, Royal Bank of Canada lowered their target price on Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating on the stock in a research note on Thursday. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $14.44.

Perspective Therapeutics Trading Down 4.3 %

NYSE CATX opened at $2.20 on Monday. The business’s fifty day moving average is $2.94 and its 200-day moving average is $6.29. Perspective Therapeutics has a one year low of $2.19 and a one year high of $19.05.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Y Intercept Hong Kong Ltd bought a new stake in shares of Perspective Therapeutics during the fourth quarter valued at about $33,000. Intech Investment Management LLC purchased a new position in Perspective Therapeutics during the third quarter valued at approximately $137,000. Aigen Investment Management LP bought a new stake in Perspective Therapeutics during the 4th quarter worth approximately $34,000. National Bank of Canada FI increased its holdings in Perspective Therapeutics by 549,900.0% during the 4th quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock worth $35,000 after acquiring an additional 10,998 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Perspective Therapeutics in the 3rd quarter worth approximately $152,000. Institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.